Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Breast Cancer Research and Treatment|January 4, 2021
Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?N I Bouwer, T G Steenbruggen, J van Rosmalen, et al.
Prostate Cancer and Prostatic Diseases|September 2, 2023
Histopathological concordance between prostate biopsies and radical prostatectomy specimens-implications of transrectal and transperineal biopsy approachesM J Hagens, L L A Ribbert, A Jager, et al.
Breast (Edinburgh, Scotland)|January 15, 2025
Implementation of model-informed precision dosing for tamoxifen therapy in patients with breast cancer: A prospective intervention studyRuben Y M van Nijnatten, Sanne M Buijs, Bram C Agema, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II studyH S Han, V Diéras, M Robson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 5, 2014
Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patientsB Mostert, A M Sieuwerts, J Kraan, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|January 7, 2020
Efficacy and safety of D,L-3-hydroxybutyrate (D,L-3-HB) treatment in multiple acyl-CoA dehydrogenase deficiencyWillemijn J van Rijt, Emmalie A Jager, Derk P Allersma, et al.
British Journal of Cancer|March 24, 2011
Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2A Osorio, R L Milne, R Alonso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2022
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerC E Geyer, J E Garber, R D Gelber, et al.
Pageof 7